New molecules affected cancer cells without proving target binding
Nine thiadiazole derivatives were screened in gastric, colorectal and breast cancer cells alongside noncancerous mouse cells. Compound 5g had a stronger effect in some cancer models, but the same selectivity did not hold in the colorectal model. Predicted binding to tubulin was not directly measured. The Scientific Reports study is an early laboratory screen, with no evidence yet of treatment efficacy or human safety.
Science··Evening
Nine chemical candidates were tested in cells
The investigators made nine thiadiazole derivatives informed by known molecules that interact with tubulin, a protein involved in cell division. They examined effects in gastric AGS cells, colorectal HT29 cells and breast MCF7 cells. Mouse fibroblasts supplied a noncancerous comparison; paclitaxel and doxorubicin were reference compounds. After different concentrations were applied for 24 and 48 hours, an MTT assay measured metabolic activity as a proxy for viability. The assay alone cannot identify how a cell dies.[1]
Compound 5g varied across cell models
At 48 hours, compound 5g had a half-maximal inhibitory concentration of 10.49 micromolar in gastric cells and 15.02 in breast cells. The value was 87.69 in colorectal cells and 53.92 in the comparator mouse fibroblasts. A lower value indicates stronger loss of viability in this assay. The selectivity ratio against noncancerous cells exceeded one for the gastric and breast models but was 0.61 for the colorectal model. That pattern does not support calling the compound selective across all cancer types.[1]
The proposed target remains unconfirmed
Computer docking placed the candidates near tubulin’s colchicine-binding site. Compound 5d had the most favorable predicted binding score, yet it did not show the strongest cellular effect. The study did not directly test tubulin polymerization or competitive colchicine binding, so the proposed mechanism remains unverified. It also did not examine animal efficacy, distribution through the body or a safe human dose. The results compare candidates for further laboratory work; they do not establish a cancer treatment.[1]
